XML 17 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations (Tables) (Income Statement [Member])
 3 Months Ended
Mar. 31, 2013
Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Regenerative Medicine – China business for the three months ended March 31, 2012, which are included in discontinued operations, were as follows (in thousands):
 
Three Months Ended March 31, 2012
Revenue
$
52.3

Cost of revenues
(30.6
)
Research and development
(103.3
)
Selling, general, and administrative
(497.3
)
Other income (expense)
(6.8
)
Loss on exit of segment
(1,138.0
)
Loss from discontinued operations
$
(1,723.7
)
As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
Cash
$
195.1

Prepaid expenses and other current assets
14.9

Property, plant and equipment, net
1,023.7

Other Assets
330.5

Accounts payable
(177.1
)
Accrued liabilities
(79.2
)
Accumulated comprehensive income
(169.9
)
Loss on exit of segment
$
1,138.0
Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Pharmaceutical Manufacturing - China business for the three months ended March 31, 2012 were as follows (in thousands):
 
Three Months Ended March 31, 2012
Revenue
$
18,284.0

Cost of revenues
(13,365.8
)
Research and development
(767.4
)
Selling, general, and administrative
(3,040.0
)
Other expense
(492.6
)
Provision for income taxes
(122.3
)
Asset impairments
—

Loss on sale of segment
—

Loss from discontinued operations
$
495.9

The Company recognized the following loss on the date of sale of its 51% interest in Erye on November 13, 2012 (in thousands):
Fair value of consideration received
$
13,397.9

Carrying value of segment non-controlling interest
6,015.0

Carrying value of segment accumulated comprehensive income
4,387.4

 
$
23,800.3

Less carrying amount of assets and liabilities sold:
 
Cash
$
8,457.5

Restricted Cash
2,918.1

Accounts Receivable
6,130.2

Inventories
15,077.7

Prepaid expenses and other current assets
957.8

Property, plant and equipment, net
38,102.0

Other assets
5,946.3

Accounts payable
(9,604.8
)
Accrued liabilities
(2,008.8
)
Bank loans
(15,133.5
)
Notes payable
(6,599.3
)
Other liabilities
(9,166.8
)
Amount due related party
(7,859.7
)
 
$
(27,216.7
)
 
 
Loss on exit of segment
$
(3,416.4
)